TrialPath
ALS (Lou Gehrig's disease) · Boston

ALS (Lou Gehrig's disease) clinical trials in Boston

19 recruiting amyotrophic lateral sclerosis studies within range of Boston. Click any trial for full eligibility criteria and contact info.

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Recruiting

The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once every 1-3 months for checkups and tests

PhasePhase 3
TypeInterventional
Age18 Years – 80 Years
WherePhoenix, Arizona, United States + 55 more
SponsorPrilenia
▾Tap for details
Apply

RAPA-501 Therapy for ALS

Recruiting

RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

PhasePhase 2 / Phase 3
TypeInterventional
Age18 Years
WhereBoston, Massachusetts, United States
SponsorRapa Therapeutics LLC
▾Tap for details
Apply

ASSESS ALL ALS Study

Recruiting

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The clinical sites are distributed across the country, and led by a group of collaborative principal investigators. Once data and samples are collected and harmonized, it will be made available to research community for future research into ALS and related neurological diseases. ASSESS protocol is specific for symptomatic ALS and control participants. This protocol includes both on-site and off-site(remote) participants. The participants will be followed for 24 months (2 years), and will include collection of medical history, clinical outcomes, and blood samples once in 4 months. Additionally, the participants will complete patient reported outcomes and speech recordings once a month. Participants who are coming into clinic may also provide optional Cerebrospinal Fluid (CSF) samples.

Phase—
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 36 more
SponsorSt. Joseph's Hospital and Medical Center, Phoenix
▾Tap for details
Apply

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Recruiting

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

PhasePhase 2
TypeInterventional
Age18 Years
WhereLa Jolla, California, United States + 48 more
SponsorZydus Therapeutics Inc.
▾Tap for details
Apply

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

NCT05724173 · Anarthria, Dysarthria, Tetraplegia
Recruiting

The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.

PhaseNA
TypeInterventional
Age18 Years – 80 Years
WhereStanford, California, United States + 1 more
SponsorLeigh R. Hochberg, MD, PhD.
▾Tap for details
Apply

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

NCT00912041 · Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis
Recruiting

The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.

PhaseNA
TypeInterventional
Age18 Years – 80 Years
WhereSacramento, California, United States + 5 more
SponsorLeigh R. Hochberg, MD, PhD.
▾Tap for details
Apply

Intermuscular Coherence as a Biomarker for ALS

Recruiting

The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from mimic diseases more accurately and earlier than currently possible. 2. Characterize IMC-βγ in neurotypical subjects by age, sex, race, and ethnicity. 3. Follow a cohort of ALS patients longitudinally to determine if IMC-βγ changes with ALS disease progression and whether such changes correlate with functional and clinical scores, or survival.

Phase—
TypeObservational
Age20 Years – 90 Years
WhereIrvine, California, United States + 3 more
SponsorUniversity of Chicago
▾Tap for details
Apply

Tofersen in Non-SOD1 ALS

Recruiting

The goal of this clinical trial is to evaluate whether tofersen is safe and effective in adults with non-SOD1 ALS. Tofersen is currently approved by the U.S. Food and Drug Administration to treat SOD1-ALS. The main questions it aims to answer are: * Does tofersen lower the levels of neurofilament light chain (NfL) in the blood and CSF of adult participants with non-SOD1 ALS? * Is tofersen safe and tolerable for adult participants with non-SOD1 ALS? * Does tofersen affect other measurements such as clinical outcomes and quality-of-life measures in participants with non-SOD1 ALS? Participants will : * Receive 100mg tofersen via lumbar puncture for 24 weeks. The doses are at the following time points: Weeks 0, 2, 4, 8, 12, 16, 20, and 24. * Complete 2 follow-up visits following the end of the dosing period at Weeks 28 and 32. * Complete a variety of questionnaires and outcome measurements such as strength and breathing testing.

PhasePhase 2
TypeInterventional
Age18 Years
WhereAtlanta, Georgia, United States + 2 more
SponsorWashington University School of Medicine
▾Tap for details

EIM Via the Myolex mScan as an ALS Biomarker

Recruiting

Amyotrophic lateral sclerosis (ALS) has been traditionally considered incurable and untreatable. But starting in the 1990s with the introduction of Riluzole, therapies are being discovered and ultimately approved for slowing disease progression. Many pharmaceutical companies continue to seek new therapeutic approaches. One critical aspect of all clinical trials is the need track to progression sensitively to identify the impact of therapy. Tools to track ALS progression must be convenient, objective, require minimal training, be easily standardized, cost-efficient, and have the potential to be applied effectively at home. There has been a push to identify accurate, objective biomarkers of ALS progression. In this study, the investigators propose to use Electrical impedance myography (EIM) to evaluate the progression of the disease. Work has shown that the EIM 50 kilohertz (kHz) phase value from one or more muscles, followed sequentially, can serve as an effective overall biomarker for assessing the rate of ALS progression for a single person.

Phase—
TypeObservational
Age18 Years
WherePhoenix, Arizona, United States + 5 more
SponsorBeth Israel Deaconess Medical Center
▾Tap for details
Apply

Healey ALS MyMatch Common Screening Protocol

Recruiting

The Healey ALS MyMatch Common Screening Protocol (MCSP) is an observational study. The main goal of the study is to help connect adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them. People who complete an MCSP Screening Visit will undergo: * clinical assessments * laboratory testing * biomarker analyses The above will be used to determine preliminary eligibility for enrolling ALS MyMatch trials. In addition to helping connect people to a Healey ALS MyMatch interventional clinical trial, the information will also be used to characterize clinical, genetic, and biofluid biomarker profiles. These profiles will help to match the right people to the right trials and evaluate the frequency of ALS-associated gene variants. Blood samples and DNA will also be stored for future ALS and biomarker research.

Phase—
TypeObservational
Age18 Years
WhereDavie, Florida, United States + 3 more
SponsorMassachusetts General Hospital
▾Tap for details
Apply

Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study

Recruiting

Following completion of the ALS Early Feasibility Study of the MyoRegulator® device for treatment of ALS (NCT06165172), the CALM study will further assess the feasibility of the MyoRegulator® device to treat ALS in an expanded number of individuals with ALS. CALM will gather additional preliminary evidence of clinical safety and potential effectiveness in this patient population with a longer follow-up period and additional secondary endpoints in a single-arm study prior to commencing a larger sham-controlled pivotal trial.

PhaseNA
TypeInterventional
Age18 Years – 80 Years
WhereBoston, Massachusetts, United States
SponsorPathMaker Neurosystems Inc.
▾Tap for details
Apply

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT04363684 · Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Recruiting

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

Phase—
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 25 more
SponsorMayo Clinic
▾Tap for details
Apply

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

Recruiting

PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS). Two escalating dose (low dose and high dose) cohorts are planned. The duration of the study will be a maximum of 5 years and 5 weeks (265 weeks) for each participant. The screening period may last up to 5 weeks to complete screening procedures.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 8 more
SponsorVector Y Therapeutics
▾Tap for details
Apply

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

NCT06665165 · ALS
Recruiting

This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS).

PhasePhase 1
TypeInterventional
Age18 Years
WhereLa Jolla, California, United States + 13 more
SponsorAmylyx Pharmaceuticals Inc.
▾Tap for details
Apply

Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

NCT07357428 · Amyotrophic Lateral Sclerosis, Neuromuscular Disease, Stroke
Recruiting

The Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI). The Connexus BCI is intended to be used as: (1) an assistive communication device to decode imagined language correlates and speech for patients with impaired communication as a result of severe loss of voluntary motor control; and (2) to provide control of computer devices for individuals with severe loss of voluntary motor control of the upper extremity.

PhaseNA
TypeInterventional
Age22 Years – 75 Years
WhereSacramento, California, United States + 2 more
SponsorParadromics
▾Tap for details
Apply

Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?

Recruiting

Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. The gold standard of care for people with ALS is multidisciplinary clinics (MDC). In these multidisciplinary clinics, which occur every 3 to 4 months, people with ALS see up to 12 different healthcare providers (e.g., speech therapy, physical therapy, the ALS doctor). These clinics can last from three to five hours, and across these three to five hours people with ALS and their caregivers receive a lot of information that is critical to the care and quality of life for people with ALS. However, this information can be difficult to remember given the large amount of information that is conveyed. The current standard for providing take-home information about the visit is to provide patients with a written after-visit summary and access to their doctor's notes about the visit, typically through the patient portal. This study tests whether providing participants with video recordings of their MDC visits improves their quality of life and the quality of life of their caregivers. The study will enroll 400 pairs of people with ALS and their caregivers from eight different sites in the United States. Half of the participants in the study will receive their after-visit summary notes (the NOTES condition) and the other half of the participants will receive both their summary notes, but will also receive video recordings of their MDC visits that they can watch on their own at home (the VIDEO condition). The study will last for 12 months, with participants receiving NOTES or VIDEO at each of their regularly-scheduled MDCs during the 12 months. The study will test whether caregiver and patient participants in the VIDEO condition experience better quality of life than those in the NOTES condition at 1 month, 6 months, and 12 months from study enrollment. The results of this study will help determine what is the most effective approach to communicating MDC information to people with ALS and their caregivers.

PhaseNA
TypeInterventional
Age18 Years
WhereScottsdale, Arizona, United States + 6 more
SponsorTrustees of Dartmouth College
▾Tap for details
Apply

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

NCT05137665 · Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder
Recruiting

The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-weekly in a subset of participants. ALS participants will be asked to come to the clinic for 5 study visits approximately every 4 months. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.

Phase—
TypeObservational
Age18 Years
WherePhoenix, Arizona, United States + 11 more
SponsorTarget ALS Foundation, Inc.
▾Tap for details
Apply

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034 · Adjustment Disorder
Recruiting

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WhereBirmingham, Alabama, United States + 32 more
SponsorReunion Neuroscience Inc
▾Tap for details
Apply

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

Recruiting

In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for participant with a certain type of amyotrophic lateral sclerosis, also known as ALS. This type is in participant who have a mutation in the superoxide dismutase 1 gene, also known as SOD-1. This is known as an "observational" study, which collects health information about study participants without changing their medical care. Participants for this study will be found using 2 different groups of study research centers that help provide clinical care for participant with ALS. These groups are in Europe and the United States and are called: * the Precision-ALS programme * the ALS/Motor Neuron Disease (MND) Natural History Consortium (NHC) The main goal of this study is to collect safety information in participants with SOD-1 ALS who were in either of the groups. The main question researchers want to answer in this study is: * What are the characteristics of the participants in this study? * How many participants had serious adverse events (SAEs), including ones that affect the brain, spinal cord, or nerves? An adverse event is a health problem that may or may not be caused by a drug during the study. An adverse event is considered serious when it results in death, is life-threatening, causes lasting problems, or requires hospital care. Researchers will also learn more about: * How many participants develop other health conditions or become pregnant, including how the pregnancy turned out * Why and when participants stopped treatment This study will be done as follows: * Participants will be screened to check if they can join the study. * Data from the participants' regular visits to their clinic will be collected based on which study research center they are in. * Each participant will be in the study until they decide to leave or until death. Currently, the study is planned to last at least 7 years.

Phase—
TypeObservational
Age18 Years
WhereBoston, Massachusetts, United States
SponsorBiogen
▾Tap for details
Apply